Lack of association of IL-10 gene polymorphisms with prostate cancer: Evidence from 11,581 subjects

European Journal of Cancer

Volumn 47, Issue 7, 2011, Pages 1072-1079

  Zou, Yan Feng ^a   Wang, Fang ^a   Feng, Xiao Liang ^a   Tian, Yang Hua ^a   Tao, Jin Hui ^b   Pan, Fa Ming ^a   Huang, Fen ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

Genetic polymorphisms; Interleukin 10; Meta analysis; Prostate cancer

Indexed keywords

INTERLEUKIN 10;

ARTICLE; ASIAN; CAUCASIAN; DNA POLYMORPHISM; ETHNIC DIFFERENCE; GENETIC ANALYSIS; GENOTYPE; HUMAN; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER;

ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CYTOKINES; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; INTERLEUKIN-10; MALE; ODDS RATIO; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 79953699020     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.11.034     Document Type: Article

References (34)

1. Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A. Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer 2010;46(17):3040-52.
2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46(4):765-81.
3. Lesko SM, Rosenberg L, Shapiro S. Family history and prostate cancer risk. Am J Epidemiol 1996;144(11):1041-7. (Pubitemid 26404810)
4. Sun J, Turner A, Xu J, Grönberg H, Isaacs W. Genetic variability in inflammation pathways and prostate cancer risk. Urol Oncol 2007;25(3):250-9. (Pubitemid 46670748)
5. Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 2005;78(5):1043-51. (Pubitemid 41572467)
6. Matsuda M, Salazar F, Petersson M, et al. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 1994;180(6):2371-6.
7. Kong F, Liu J, Liu Y, et al. Association of interleukin-10 gene polymorphisms with breast cancer in a Chinese population. J Exp Clin Cancer Res 2010;29:72.
8. Eskdale J, Kube D, Tesch H, Gallagher G. Mapping of the human IL10 gene and further characterization of the 5′ flanking sequence. Immunogenetics 1997;46(2):120-8. (Pubitemid 27234709)
9. Kingo K, Rätsep R, Kõks S, et al. Influence of genetic polymorphisms on interleukin-10 mRNA expression and psoriasis susceptibility. J Dermatol Sci 2005;37(2):111-3. (Pubitemid 40126829)
10. Crawley E, Kay R, Sillibourne J, et al. Polymorphic haplotypes of the interleukin-10 50 flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 1999;42(6):1101-8. (Pubitemid 29268946)
11. Liu J, Song B, Bai X, et al. Association of genetic polymorphisms in the interleukin-10 promoter with risk of prostate cancer in Chinese. BMC Cancer 2010;10(1):456.
12. VanCleave TT, Moore JH, Benford ML, et al. Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk. Prostate 2010;70(4):341-52.
13. Leon AJ, Leon VJ, Garcia J, Urrutia M. Interleukin gene polymorphism in patients with prostate cancer. Tissue Antigens 2010;75(5):637.
14. Wang MH, Helzlsouer KJ, Smith MW, et al. Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. Prostate 2009;69(8):874-85.
15. Kesarwani P, Ahirwar DK, Mandhani A, et al. IL-10-1082 G > A: a risk for prostate cancer but may be protective against progression of prostate cancer in North Indian cohort. World J Urol 2009;27(3):389-96.
16. Omrani MD, Bazargani S, Bageri M. Interlukin-10, interferon-γ and tumor necrosis factor-α genes variation in prostate cancer and benign prostatic hyperplasia. Curr Urol 2008;2(4):175-80.
17. Zabaleta J, Lin HY, Sierra RA, et al. Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis 2008;29(3):573-8. (Pubitemid 351404874)
18. Faupel-Badger JM, Kidd LC, Albanes D, et al. Association of IL-10 polymorphisms with prostate cancer risk and grade of disease. Cancer Causes Control 2008;19(2):119-24.
19. Eder T, Mayer R, Langsenlehner U, et al. Interleukin-10 [ATA] promoter haplotype and prostate cancer risk: a population-based study. Eur J Cancer 2007;43(3):472-5. (Pubitemid 46177585)
20. Michaud DS, Daugherty SE, Berndt SI, et al. Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res 2006;66(8):4525-30.
21. Xu J, Lowey J,Wiklund F, et al. The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2005;14(11 Pt. 1):2563-8. (Pubitemid 41752716)
22. McCarron SL, Edwards S, Evans PR, et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 2002;62(12):3369-72. (Pubitemid 34651380)
23. Munafo MR, Flint J. Meta-analysis of genetic association studies. Trends Genet 2004;20(9):439-44. (Pubitemid 39094573)
24. Cochran WG. The combination of estimates from different experiments. Biometrics 1954;10(1):101-29.
25. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21(11):1539-58. (Pubitemid 34746062)
26. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22(4):719-48.
27. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177-88. (Pubitemid 17189972)
28. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997;315(7109):629-34. (Pubitemid 27387172)
29. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996;273(5281):1516-7. (Pubitemid 26301653)
30. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003;33(2):177-82. (Pubitemid 36177070)
31. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet 2001;29(3):306-9. (Pubitemid 33096456)
32. Mocellin S, Marincola F, Rossi CR, Nitti D, Lise M. The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine Growth Factor Rev 2004;15(1):61-76. (Pubitemid 38121291)
33. Filella X, Alcover J, Zarco MA, et al. Analysis of type T1 and T2 cytokines in patients with prostate cancer. Prostate 2000;44(4):271-4.
34. Turner DM, Williams DM, Sankaran D, et al. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997;24(1):1-8. (Pubitemid 27050850)